MedTrace Logo

Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections

NCT03189537 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2017-06-16

No results posted yet for this study

Summary

The purpose of the study was to evaluate efficacy of prophylactic Ingavirin intake by people having contact with sick people infected with influenza and other acute respiratory viral infections

Conditions

Interventions

DRUG

Ingavirin (Imidazolyl Ethanamide Pentandioic Acid)

Broad-spectrum antiviral agent

DRUG

Placebo oral capsule

Placebo capsule to match Ingavirin capsule

Sponsors & Collaborators

  • Valenta Pharm JSC

    lead INDUSTRY

Principal Investigators

  • Ekaterina Zakharova, MD, PhD · Valenta Pharm JSC

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-03
Primary Completion
2011-04-19
Completion
2011-10-10

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03189537 on ClinicalTrials.gov